Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by and welcome to Ascendus Pharma first quarter 2025 earnings conference call. At this time, all participants are in the listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would like now to turn the conference over to Scott Smith, Vice President and Chief Financial Officer. Please go ahead, sir. Thank you so much, operator. And thank you, everyone, for joining our first quarter 2025 Financial Results Conference Call. I'm Scott Smith, Chief Financial Officer at Ascendus Pharma. Joining me on the call today are Yen Mickelson, President and Chief Executive Officer, Sherry Glass, Chief Business Officer, Jay Wu, Executive Vice President and President Ascendus US, and Amy Hsu, Chief Medical Officer. Before we begin, I'd like to remind you that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act. Examples of such statements may include but are not limited to statements regarding our commercialization and continued development of Skytrofa and Yorvapath for the U.S., European, and other markets, as well as certain financial expectations, our pipeline candidates, and our expectations with respect to their continued progress and potential commercialization. Our strategic plans, partnerships, and investments, our goals regarding our clinical pipeline, including the timing of clinical results and trial...